TIBCS 2024

Program
Time (UTC+8) Topic Speaker Moderator Abstract Slides Video
08:30 - 09:00 Registration & Opening
Shou-Tung Chen
 Video
09:00 - 09:30 Global International-Initiated Trial (PATHWAY Trial) in Asian Countries for HR-Positive/HER2-Negative Advanced Breast Cancer
Kenji Tamura
King-Jen Chang
 Video
09:30 - 10:00 Are All Triple Negative Breast Cancers the Same?
Jorge S. Reis-Filho
Cheng-Ping Yu
 Video
10:00 - 10:30 Current Status and Future Prospects of Immunotherapy in Breast Cancer Treatment: Past, Present, and Future
Tan Jing Ying Tira
Ching-Hung Lin
 Video
10:30 - 10:50 Coffee Break
10:50 - 11:20 Precision Immunotherapy for TNBC: From Clinical Factors to Tumor Microenvironment
Giampaolo Bianchini
Hsien-Kun Chang
Ming-Feng Hou
 Video
11:20 - 11:50 From Consistent 1L CDK4/6i Evidence-Based Survival Benefit to Real-World Clinical Practice in HR+HER2- mBC
Shih-Yu Huang
Kuo-Ting Lee
 Video
11:50 - 12:10 Panel Discussion
Giampaolo Bianchini
Jorge S. Reis-Filho
Tan Jing Ying Tira
Takashi Ishikawa
Ming-Feng Hou
 Video
12:10 - 12:50 Docetaxel, Aging Like a Fine Wine
Chun-Yu Liu
Liang-Chih Liu
 Video
12:50 - 13:10 Coffee Break
13:10 - 13:40 The Sustainable Efficacy of CDK4/6 Inhibitor Therapy in HR+/Her2- Node+ High Risk Early Breast Cancer
Nadia Harbeck
Dar-Ren Chen
 Video
13:40 - 14:10 Adjuvant Treatment for Young Age ER+ Early Breast Cancer (EBC)
Prudence Francis
Shyr-Ming Sheen-Chen
 Video
14:10 - 14:40 Bridging Treatment Gaps for Stage II and III HR+/HER2- Early Breast Cancer with CDK4/6 Inhibitors
Stephen Chia
Fang-Ming Chen
 Video
14:40 - 15:00 Coffee Break
15:00 - 15:30 Long-Term Survival Benefits of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer: Insights from Real-World Evidence
Hope S. Rugo
Fiona Tsui-Fen Cheng
 Video
15:30 - 16:00 Novel Strategies to Overcome Resistance to Endocrine Therapy in HR+ aBC: From Biological Perspectives to Clinical Advances
Javier Cortés
Tsu-Yi Chao
 Video
16:00 - 16:20 Panel Discussion
Javier Cortés
Prudence Francis
Hope S. Rugo
Shinji Ohno
Shin-Cheh Chen
 Video
16:20 - 16:50 Navigating ADC to Clinical Success With the Learning from Current Research
Leif Ellisen
Chiun-Sheng Huang
 Video
16:50 - 17:20 Riding the Wave of Innovation: The evolving landscape of ADCs in Breast Cancer Treatment
Paolo Tarantino
Jiun-I Lai
 Video
17:20 - 17:50 Optimizing Survival: Individualized Adjuvant Strategies for Maximizing Neoadjuvant Benefits
Sibylle Loibl
Ling-Ming Tseng
 Video
17:50 - 18:10 Panel Discussion
Leif Ellisen
Sibylle Loibl
Paolo Tarantino
Yen-Shen Lu
 Video
Time (UTC+8) Topic Speaker Moderator Abstract Slides Video
10:30 - 10:50 Screening, Diagnosis and Surveillance Between East and West
Eun Sook Ko
10:50 - 11:10 Difference in Surgical Considerations and Oncoplastic Surgery Between East and West
Wen-Ling Kuo
11:10 - 11:30 Difference in Medical Considerations and Survivorship Between East and West
Hyun Jo Youn
11:30 - 12:00 Panel Discussion:What Are the Unique Surgical Needs in Asian Population and How to Meet Them?
Eun Sook Ko
Wen-Ling Kuo
Hyun Jo Youn
Chih-Chiang Hung
Hee Jeong Kim
Ming-Yang Wang
13:00 - 13:05 Young Doctors Forum/Debate Opening
Chi-Cheng Huang
13:05 - 13:30 [YDF] How to ask translational questions?
Shiuan Chen
Hsu-Huan Chou
13:30 - 13:55 [YDF] Agonies of Young Doctors within the South Korean Health Care System
Jun Won Min
Hsu-Huan Chou
13:55 - 14:00 [YDF] Q&A
Hsu-Huan Chou
14:00 - 14:40 [YDD Topic 1] Should ALND Be Performed in ypN1micro Luminal Breast Cancer Patient with Initial cN1 After Neoadjuvant Chemotherapy?
Yen-Jen Chen
Bo-Fang Chen
Hsu-Huan Chou
Chia-Hui Chu
An-Chieh Feng
Joan Gan Cheau Yan
Chih-Hao Huang
Sae Byul Lee
Sue Zann Lim
Zhu-Jun Loh
Hitomi Mori
Minjin Ulaankhuu
Youri Park
Yokoe Takamichi
Tan Ying Ching
Kaori Tane
Azzaya Terbish
Wen-Ling Kuo
14:40 - 15:20 [YDD Topic 2] Should Adjuvant Pembrolizumab Be Considered in Early TNBC Patients Achieving pCR After Neoadjuvant Chemotherapy Combined with Immunotherapy?
Cheng-Wei Chou
Jeffrey Hing Jun Xian
Shih-Yu Huang
Po-Hsiang Huang
Ji-Jung Jung
Ki Jo Kim
Cho Eun Lee
Young-Jin Lee
Soo-Young Lee
Young-Won Lee
Chia-Chen Li
Joseph Lin
Kawon Oh
Meng-Ting Peng
Hidenobu Takahashi
I-Chen Tsai
Ming-Han Yang
Chun-Yu Liu
15:20 - 15:30 [YDD] Q&A Closing
Jeong Eon Lee
Time (UTC+8) Topic Speaker Moderator Abstract Slides Video
10:50 - 11:00 [B006] Collagen family proteins, thrombospondin 1 and lumican are differentially expressed across breast cancer subtypes by functional proteomics: a preliminary study with bioinformatics analysis
Chi-Cheng Huang
11:00 - 11:10 [B003] Integrative Omics Analysis Reveals DTX1 as a Key Marker and Drug Target in Breast Cancer
Yen-Dun Tzeng
11:10 - 11:20 [B009] Therapeutic Co-Targeting of the BTK/HER2 Axis Induces Iron Accumulation to Overcome Trastuzumab Resistance in HER2-Positive Breast Cancer
Chih-Ming Su
11:20 - 11:30 [B004] ATP synthasome contributes to efficient energy flux in malignant breast cancer
Chia-Jung Li
11:30 - 11:40 [B016] The application of a PI3K inhibitor and an AKT inhibitor in HER2-positive breast cancer cells with resistance to HER2-directed antibody-drug conjugates
Wei-Pang Chung
11:40 - 11:50 [B013] Targeting the USP7-CDK1 axis suppresses estrogen receptor-positive breast cancer progression
Joseph Lin
11:50 - 12:00 [B015] SLC6A14-Mediated Glutamine Metabolism Reprogramming Enhances Cancer Stemness for Early Onset of Breast Cancer
Meng-Xia Su
12:00 - 12:10 [B001] Discovery and Biological Evaluation of a Novel Inhibitor for Human Breast Cancer Treatment
Cheng-Chiao Huang
12:10 - 12:20 [C025] Enhancing the Detection of Contralateral Breast Cancer in Breast Cancer Survivors Using Artificial Intelligence
Jijung Jung
12:20 - 12:30 [C013] Pattern of failure and timing of progression on CDK4/6 inhibitor as first line therapy for HR+HER2- metastatic breast cancer invading different organ
Ruoh-Yun Kao
13:10 - 13:20 [B010] Prognostic effects of ABCB1 and TMEM14B expression in triple-negative breast cancer
Sin-Hua Moi
13:20 - 13:30 [B025] Co-targeting PD-L1 and CDK4 benefits plasticizer-associated early-onset breast cancer
Shu-Wei Hu
13:30 - 13:40 [B024] Mechanistic Insights into Melittin’s Efficacy Against Tamoxifen-Resistant Breast Cancer: Apoptosis, Proliferation, and Migration Modulation
Min-Hua Wu
13:40 - 13:50 [B005] LOC100506691, a long noncoding RNA, acts as novel oncogene in regulating breast cancer growth
Kian-Hwee Chong
13:50 - 14:00 [B014] Molecular characterization of HER2 low breast cancers reveals a biologically and clinically distinct entity with heterozygous loss of ERBB2
Xintao Qiu
14:00 - 14:10 [C016] Using Bilateral Thoracoabdominal Flaps for Extensive Defects After Bilateral Mastectomy for Inflammatory Breast Cancer
Ryohei Katsuragi
14:10 - 14:20 [C061] Case Report of Stereotactic Body Radiation Therapy for Oligometastatic Breast Cancer Patient
Masahiro Yoshida
14:20 - 14:30 [B023] exoLinc-p21s: a short lincRNA-p21-engineered exosome as a chemosensitizer for targeting DDB2-mediated DNA repair
Yu-Hao He
14:30 - 14:40 [C009] LXPB5268 combined with neoadjuvant chemotherapy in early-stage Triple-Negative Breast Cancer patients
Chin-Yin Kuo
15:00 - 15:10 [C037] Multi-omics and spatial transcriptomics unveil the role of ferroptosis suppressor FANCD2 in clinicopathology and predicting immunotherapy response in breast cancer
Hung-Yu Lin
15:10 - 15:20 [C074] Combination of endocrine therapy, gonadotropin-releasing hormone agonist, and immunotherapy enhance immune activation in premenopausal ER+/HER2- metastatic breast cancer patients: final updates from PEER study
I-Chun Chen
15:20 - 15:30 [C030] Circulating CD3+CD8+ T lymphocytes as indicators of disease status in patients with early breast cancer
Hui-Ping Hsu
Time (UTC+8) Topic Speaker Moderator Abstract Slides Video
08:20 - 08:50 The Current Role of Combination Chemotherapy in Metastatic Breast Cancer Treatment
Ta-Chung Chao
Nei-Min Chu
 Video
08:50 - 09:20 Axillary Surgery in Clinically Node Negative and Positive Disease: Current Indication
Jai Min Ryu
Yao-Jen Chang
 Video
09:20 - 10:00 Current Topics in Breast Cancer Radiation Oncology: Axillary Management, Multi-Centric Disease, and Second Breast-Conserving Therapy
Philip Poortmans
Jyh-Cherng Yu
 Video
10:00 - 10:30 How to Avoid Axillary Dissection in Breast Cancer Patients with Metastatic Axillary Lymph Nodes on Preoperative Ultrasound?
Jana de Boniface
Wen-Hung Kuo
 Video
10:30 - 10:50 Panel Discussion
Jana de Boniface
Philip Poortmans
Wonshik Han
Guo-Shiou Liao
 Video
10:50 - 11:10 Coffee Break
11:10 - 11:40 Breast Cancer Biology for Precision Medicine
Christos Sotiriou
Wen-Ling Kuo
 Video
11:40 - 12:10 Diagnostic and Therapeutic Considerations in Tumor Microenvironments
Mark Pegram
Chi-Cheng Huang
 Video
12:10 - 12:50 Real World Evidence: Astragalus polysaccharides Injection and Breast Cancer Patients with Cancer-related Fatigue
Ming-Shen Dai
Kun-Ming Rau
 Video
13:10 - 13:40 Unmet Needs in Early-Stage HER2-Positive Breast Cancer: The Benefit of Extended Adjuvant Treatment
Hsu-Huan Chou
Shih-Che Shen
 Video
13:40 - 14:10 Cardio-Oncology: Protecting the Heart as Curative Breast Cancer Treatment
Wei-Ting Chang
Hsien-Tang Yeh
 Video
14:10 - 14:40 Navigating the Intersection of Breast cancer and Bone Health: the Role of Denosumab in Preventing Skeletal-Related Events
Li-Kun Ko
Chin-Yao Lin
 Video
14:40 - 15:00 Coffee Break
15:00 - 15:30 Potential Role of TIL Assessment in Clinical Practice
Sherene Loi
Chen-Hsiang Chang
 Video
15:30 - 15:40 What Should We Do on Monday Morning:TNBC?
Yuan-Ching Chang
Shou-Tung Chen
 Video
15:40 - 15:50 What Should We Do on Monday Morning:ER+?
Dwan-Ying Chang
Shou-Tung Chen
 Video
15:50 - 16:40 What Should We Do on Monday Morning: HER2+?
Wei-Pang Chung
Shou-Tung Chen
 Video
16:00 - 16:20 Award Ceremony & Closing
Shou-Tung Chen